- (i) providing a cell, said cell comprising,
 - a first heterologous promoter operably linked to a first a) polynucleotide encoding a functional Ga15 protein having at least 95 % sequence homology to SEQ. ID. NO. 2,
 - a second heterologous promoter operably linked to a second b) polynucleotide encoding a reporter gene,
 - a third heterologous promoter operably linked to a third c) polynucleotide encoding said GPCR,

wherein said cell stably expresses said $G\alpha 15$ protein at sufficient levels to permit promiscuous coupling to said GPCR,

wherein said GPCR is not naturally expressed in said cell, and

wherein said second heterologous promoter is directly or indirectly modulated by the activity of said $G\alpha 15\ protein;$

- (ii) contacting said cell with said ligand; and
- (iii)detecting a change in reporter gene expression by comparing reporter gene expression prior to addition of said ligand with reporter gene expression after addition of said ligand.
- 64. (Canceled)
- 65. (Canceled)
- 66. The method of claim 63, wherein said GPCR is a taste receptor.

67. (Amended) The method of claim 63, wherein said reporter gene is selected from the group consisting of luciferase, GFP, chloramphenical acetyl transferase, βgalactosidase, \(\beta \)—lactamase and secreted alkaline phosphatase.

- 68. The method of claim 63, further comprising contacting said cell with a compound that increases calcium levels inside said cell.
- 69. The method of claim 68, wherein said compound is selected from the group consisting of ionomycin and thapsigargin.
- 70. The method of claim 68, further comprising contacting said cell with phorbol myristate acetate or an analog thereof.

71. (Twice amended) A method for identifying a GPCR for a given ligand, the method comprising:

providing a cell, said cell comprising, i)

a first heterologous promoter operably linked to a first polynucleotide encoding a functional Gα15 protein having at least 95 % sequence homology to SEQ. ID. NO. 2, and

a second heterologous promoter operably linked to a second polynucleotide encoding said GPCR,

wherein/said cell stably expresses said Ga15 protein at sufficient levels to permit promiscuous coupling to said GPCR and wherein said GPCR is normally coupled to either $G\alpha_i,\,G\alpha_s$ or $G\alpha_{12}$ in the absence of said Ga15 protein, and

wherein said GPCR is not naturally expressed in said cell;

contacting said cell with said ligand; and

detecting a change in a signal with a signal transduction detection system by comparing said signal prior to addition of said ligand with said signal after addition of said ligand, and

wherein said signal transduction detection system comprises a dye.

72. (Canceled)

ii)

iii

73. (Canceled)

Auro-008.02us Negulescu et al. Response to office action 3



74. The method of claim 71, wherein said signal transduction detection system comprises an intracellular calcium indicator.

Dy

765

75. (Twice amended) A method of identifying a ligand for a GPCB, the method comprising:

i) contacting a cell with a test chemical, said cell comprising,
a first heterologous promoter operably linked to a first
polynucleotide encoding a functional Go/15 protein having at least 95 % sequence
homology to SEQ. ID. NO. 2, and

a second heterologous promoter operably linked to a second polynucleotide encoding said GPCR,

wherein said cell stably expresses said G α 15 protein at sufficient levels to permit promiscuous coupling to said GPCR and wherein said GPCR is normally coupled to either G α_i , G α_s or G α_{12} in the absence of said G α 15 protein and,

wherein said GPCR is not naturally expressed in said cell; detecting a change in a signal with a signal transduction detection system by comparing said signal prior to addition of said test chemical with said signal after addition of said test chemical,

wherein said signal transduction detection system comprises a dye.

76. (Canceled)

ii)

77. (Canceled)

SUM FG

78. The method of claim 75, wherein said signal transduction detection system comprises an intracellular calcium indicator.

05

79. (Twice amended) The method of claim 75, further comprising comparing a signal from a first plurality of cells in the presence of said test chemical with either:

Auro-008.02us

Negulescu et al.

Response to office action

OS cont'o

- i) a signal from a second plurality of cells in the presence of said test chemical, wherein said second plurality of cells lack said Gα15 protein or
- ii) a signal from said first plurality of cells in the absence of said test chemical.

5/10/

80. The method of claim 75, wherein said detecting comprises fluorescence detection.

06

81. (Twice amended) A method of identifying a ligand for a GPCR, the method comprising;

Ry

- i) contacting a cell with a test chemical, said cell comprising,
 - a) a first heterologous promoter operably linked to a first polynucleotide encoding a functional G α 15 protein having at least 95 % sequence homology to SEQ. ID. NO. 2,
 - b) a second heterologous promoter operably linked to a second polynucleotide encoding a reporter gene,
 - c) a third heterologous promoter operably linked to a third polynucleotide encoding said GPCR,

wherein said cell stably expresses said $G\alpha 15$ protein at sufficient levels to permit promiscuous coupling to said GPCR,

wherein said GPCR is not naturally expressed in said cell, and

wherein said second heterologous promoter is directly or indirectly modulated by the activity of said $G\alpha15$ protein;

detecting a change in reporter gene expression by comparing reporter gene expression prior to addition of said ligand with reporter gene expression after addition of said ligand.

82. (Canceled)

ii)

83. (Canceled)

Auro-008.02us Negulescu et al. Response to office action SUD FT

84. The method of claim 81, wherein said detecting comprises fluorescence detection.

O Juss

85. (Amended) The method of claim 81, wherein said reporter gene is selected from the group consisting of luciferase, GFP, chloramphenical acetyl transferase, β-galactosidase, β-lactamase and secreted alkaline phosphatase.

SUBFA

- 86. The method of claim 81, further comprising contacting said cell with a compound that increases calcium levels inside said cell.
- 87. The method of claim 86, wherein said compound is selected from the group consisting of ionomycin and thapsigargin.

47

88. The method of claim 81, further comprising contacting said cell with phorbol myristate acetate or an analog thereof.

08

- 89. (Twice amended) The method of claim 81, further comprising comparing a signal from a first plurality of cells in the presence of said test chemical with either:
 - i) a signal from a second plurality of cells in the presence of said test chemical, wherein said second plurality of cells lack said Gα15 protein, or
 - ii) a signal from said first plurality of cells in the absence of said test chemical.

7/3/

- 90. (Twice amended) A method for identifying a modulator of signal transduction mediated by GPCR activation in a cell, the method comprising:
 - a) contacting a cell with a test chemical, said cell comprising,

a first heterologous promoter operably linked to a first polynucleotide encoding a functional G α 15 protein having at least 95 % sequence homology to SEQ.

ID. NO. 2, and

a second heterologous promoter operably linked to a second polynucleotide encoding said GPCR,

Auro-008.02us

Negulescu et al.

Response to office action

OS CONTIN

Cont E8 wherein said cell stably expresses said $G\alpha15$ protein at sufficient levels to permit promiscuous coupling to said GPCR and wherein said GPCR is normally coupled to either $G\alpha_i$, $G\alpha_s$ or $G\alpha_{12}$ in the absence of said $G\alpha15$ protein, and

wherein said GPCR is not naturally expressed in said cell;

- b) contacting said cell with a ligand that, in the absence of said test chemical, activates signal transduction via said GPCR in said cell, and
- c) detecting a change in a signal with a signal transduction detection system by comparing said signal prior to addition of said test chemical with said signal after addition of said test chemical.
- 91. (Canceled)
- 92. (Canceled)

sill Fre

93. The method of claim 90, wherein said signal transduction detection system comprises an intracellular calcium indicator.

Dr

- 94. (Twice amended) A method for identifying a modulator of signal transduction in a cell, the method comprising:
 - i) contacting a cell with a test chemical, said cell comprising,
 - a) a first heterologous promoter operably linked to a first polynucleotide encoding a functional G α 15 protein having at least 95 % sequence homology to SEQ. ID. NO. 2,
 - b) a second heterologous promoter operably linked to a second polynucleotide encoding a reporter gene,
 - c) a third heterologous promoter operably linked to a second polynucleotide encoding said GPCR,

wherein said cell stably expresses said $G\alpha15$ protein at sufficient levels to permit promiscuous coupling to said GPCR, and

Auro-008.02us Negulescu et al. Response to office action Cost E9

wherein said second heterologous promoter is directly or indirectly modulated by the activity of said $G\alpha15$ protein, and wherein said GPCR is not naturally expressed in said cell;

- ii) contacting said cell with a ligand that, in the absence of said test chemical activates signal transduction via said GPCR in said cell; and
- expression prior to addition of said test chemical with reporter gene expression after addition of said test chemical.
- 95. (Canceled)
- 96. (Cancelled)

Subjet

97. The method of claim 94, wherein said detecting comprises fluorescence detection.

O Purpo

98. (Amended) The method of claim 94, wherein said reporter gene is selected from the group consisting of luciferase, GFP, chloramphenical acetyl transferase, β-galactosidase, β-lactamase and secreted alkaline phosphatase.

SW (13)

- 99. The method of claim 94, further comprising contacting said cell with a compound that increases calcium levels inside said cell.
- 100. The method of claim 99, wherein said compound is selected from the group consisting of ionomycin and thapsigargin.

7/10

101.

The method of claim 94, further comprising contacting said cell with phorbol myristate acetate or an analog thereof.

D|| 102.

- (Twice amended) A method of functionally profiling a test chemical comprising the steps of.
- i) contacting a panel of cells with a test chemical, said panel of cells

Auro-008.02us

Negulescu et al. Response to office action 0110 cont 10

Court

comprising, a plurality of cell clones, each cell clone comprising a) a first heterologous promoter operably linked to a first polynucleotide encoding a functional G α 15 protein having at least 95 % sequence homology to SEQ. ID. NO. 2,

- b) a second heterologous promoter operably linked to a second polynucleotide encoding a reporter gene,
- c) a third heterologous promoter operably linked to a third polynucleotide encoding said GPCR, wherein said cell stably expresses said $G\alpha15$ protein at sufficient levels to permit promiscuous coupling to said GPCR, wherein said second heterologous promoter is directly or indirectly modulated by the activity of said $G\alpha15$ protein,

wherein said GPCR is not naturally expressed in said cell, and wherein each cell clone differs only with respect to said GPCR that is expressed;

- ii) contacting said cell clones with a test chemical;
- iii) detecting reporter gene expression from said cell clones
- iv) comparing reporter gene expression between said cell clones.
- 103. (Canceled)
- 104. (Canceled)

STO FIT

105. The method of claim 102, wherein said detecting comprises fluorescence detection.

106.

(Amended) The method of claim 102, wherein said reporter gene is selected from the group consisting of luciferase, GFP, chloramphenical acetyl transferase, β -galactosidase, β -lactamase and secreted alkaline phosphatase.

The state of the s

107. The method of claim 102, further comprising contacting said cell with a

Auro-008.02us Negulescu et al. Response to office action Compound that increases calcium levels inside said cell.

- 108. The method of claim 107, wherein said compound is selected from the group consisting of ionomycin and thapsigargin.
- 109. The method of claim 107, further comprising contacting said cell with phorbol myristate acetate or an analog thereof.

013

110. (Amended) The method of claim 67, further comprising contacting said cell with a reporter gene substrate.

(Amended) The method of claim 67, wherein said reporter gene is β -lactamase.

112. (Amended) The method of claim 85, further comprising contacting said cell with a reporter gene substrate.

113. (Amended) The method of claim 85, wherein said reporter gene is β-lactamase.

114. (Amended) The method of claim 98, further comprising contacting said cell with a reporter gene substrate.

215. (Amended) The method of claim 98, wherein said reporter gene is β -lactamase.

- 116. (Amended) The method of claim 106, further comprising contacting said cell with a reporter gene substrate.
- 117. (Amended) The method of claim106, wherein said reporter gene is β -lactamase.
- 118. (Amended) The method of claim 110, wherein said reporter gene substrate is CCF2.

013 contis

119. (Amended) The method of claim 112, wherein said reporter gene substrate is CCF2.

Ont 120.

(Amended) The method of claim 114, wherein said reporter gene substrate is CCF2.

- 121. (Amended) The method of claim 116, wherein said reporter gene substrate is CCF2.
- 122. (Amended) The method of claim 75, wherein said GPCR is selected from the group consisting of muscarinic receptors, nictonic acetylcholine receptors, GABA receptors, glutamate receptors, adrenergic receptors, dopamine receptors and serotonin receptors.
- 123. (Amended) The method of claim 81, wherein said GPCR is selected from the group consisting of muscarinic receptors, nictonic acetylcholine receptors, GABA receptors, glutamate receptors, adrenargic receptors, dopamine receptors and serotonin receptors.

Please add new claims 124 to 138 as below:

DIY

--124. (New) The method of claim 90, wherein said GPCR is selected from the group consisting of muscarinic receptors, nictonic acetylcholine receptors, GABA receptors, glutamate receptors, adrenergic receptors, dopamine receptors and serotonin receptors.

July 125.

(New) The method of claim 94, wherein said GPCR is selected from the group consisting of muscarinic receptors, nictonic acetylcholine receptors, GABA receptors, glutamate receptors, adrenergic receptors, dopamine receptors and serotonin receptors.

- 126. (New) The method of claim 74, wherein said intracellular calcium indicator is Fura II.
 - 127. (New) The method of claim 78, wherein said intracellular calcium indicator is Fura II.
 - 128. (New) The method of claim 93, wherein said intracellular calcium indicator is Fura II.
 - 129. (New) The method of claim 63, wherein said second heterologous promoter is NFAT.
 - 130. (New) The method of claim 81, wherein said second heterologous promoter is NFAT.
 - 131. (New) The method of claim 94, wherein said second heterologous promoter is NFAT.
 - 132. (New) The method of claim 102, wherein said second heterologous promoter is NFAT.
 - (New) The method of claim 63, wherein said method further comprises comparing said change in reporter gene expression detected in step (iii) with a change in reporter gene expression detected in a second control cell line lacking said GPCR detected under the same conditions as in step (iii).
 - 134. (New) The method of claim 71, wherein said method further comprises comparing said change in signal detected in step (iii) with a change in signal detected in a second control cell line lacking said GPCR detected under the same conditions as in step (iii).